Rituximab in Treating Patients With Multiple Myeloma

Part of paid clinical trials in Cleveland, Ohio.

Sponsor
The Cleveland Clinic
Study ID
NCT00003554
Phase
PHASE2
Status
Completed

Conditions

  • Multiple Myeloma and Plasma Cell Neoplasm

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

  • rituximab — BIOLOGICAL
  • melphalan — DRUG
  • prednisone — DRUG

Study Details

RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them. PURPOSE: Phase II trial to study the effectiveness of the monoclonal antibody rituximab in treating patients with multiple myeloma that is newly diagnosed.

Key Dates

Start date
Nov 30, 1998
Status verified
Mar 2008
Completion
Apr 30, 2004

Study Design

Primary purpose
TREATMENT

Locations (1)

FacilityCityStateZIPSite coordinators
Cleveland Clinic Taussig Cancer CenterClevelandOhio44195-

Find similar trials in Cleveland, OH

By research site
Cleveland Clinic Taussig Cancer Center· Cleveland, OH

Related Studies